Combined Tirzepatide and Ixekizumab Therapy Shows Dual Benefits in Psoriasis: JAMA
USA: A clinical trial has found that combining tirzepatide with ixekizumab led to significant improvements in skin clearance and weight reduction in patients with moderate to severe psoriasis. The combination therapy also provided added cardiometabolic benefits without introducing new safety concerns, highlighting its potential to enhance psoriasis care in patients with obesity or overweight. The findings suggest a promising dual-treatment strategy for managing both obesity and psoriasis.
In a study published in JAMA Dermatology, Mark Lebwohl from the Icahn School of Medicine at Mount Sinai, New York, and colleagues evaluated whether targeting both inflammatory skin disease and excess weight simultaneously could improve outcomes in patients with psoriasis. Obesity is known to affect a large proportion of individuals with psoriasis, often worsening disease severity, reducing response to therapy, and increasing the risk of cardiometabolic complications.
This phase 3b, randomized, open-label clinical trial enrolled 274 adults with moderate to severe plaque psoriasis who were either overweight with related comorbidities or had obesity. Conducted across 72 sites in the United States, participants were randomly assigned to receive either ixekizumab alone or in combination with tirzepatide, alongside diet and exercise interventions. The primary endpoint was assessed at 36 weeks and focused on achieving complete skin clearance—defined as a Psoriasis Area and Severity Index (PASI) score of 100—along with at least a 10% reduction in body weight.
The trial revealed the following findings:
- The combination therapy showed clear superiority, with 27.1% of patients achieving both complete skin clearance (PASI 100) and at least 10% weight loss, compared to 5.8% with ixekizumab alone.
- A higher proportion of patients in the combination group achieved complete skin clearance (40.6%) compared to those receiving monotherapy (29.0%).
- Marked improvements were also seen in secondary outcomes, including simultaneous reduction in psoriasis severity and modest weight loss.
- A significantly greater proportion of patients in the combination group achieved at least 10% overall weight reduction.
- The dual regimen demonstrated additional benefits on cardiometabolic health, indicating broader systemic advantages.
- Findings highlight the importance of addressing obesity alongside psoriasis to improve overall disease outcomes.
- Both treatments were generally well tolerated, with safety profiles consistent with known effects of the individual drugs.
- The most commonly reported adverse events included gastrointestinal symptoms and injection-site reactions.
- Gastrointestinal side effects were more frequent in patients receiving the combination therapy.
- No new or unexpected safety concerns were identified with the combined treatment approach.
The investigators noted certain limitations, including the open-label design, absence of a tirzepatide-only treatment arm, and restriction to a US-based population. Despite these constraints, the study provides strong evidence supporting an integrated treatment approach.
Overall, the findings indicate that combining ixekizumab with tirzepatide may offer a more comprehensive strategy for managing patients with psoriasis and coexisting obesity. By simultaneously improving skin clearance and reducing weight, this dual approach could help optimize long-term outcomes and inform future clinical practice guidelines.
Reference:
Lebwohl M, Blauvelt A, Kartman CE, et al. Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial. JAMA Dermatol. Published online May 15, 2026. doi:10.1001/jamadermatol.2026.1753
Next Story